canagliflozin

AssetAlso called Canagliflozin 300 mg, JNJ-28431754, TA-7284, Teneligliptin/Canagliflozin

Fixed-dose combination of DPP-4 inhibitor teneligliptin and SGLT2 inhibitor canagliflozin to improve glycemic control

Stage
Approved
Modality
Small molecule
Target
SLC5A2
20
Indications
100
Trials
4
Developers

First approved in 2011, as ChEMBL records; approved by the FDA on Mar 29, 2013 (NDA204042). 2 approvals stand. FDA

Indications

20
  • Type 2 diabetes

    Approved, FDA

  • Diabetic kidney disease

    Approved, FDA

  • End-stage renal disease

    Approved, FDA

17 more

In the full profile

  • Target and mechanism1
  • Owner and partners4
  • Trials100
  • Evidence for its targets2
  • Competitors12
  • Aging relevance3
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets